Literature DB >> 22772980

Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.

Benjamin Ellezam, Brett J Theeler, Tobias Walbert, Aaron G Mammoser, Craig Horbinski, Bette K Kleinschmidt-DeMasters, Arie Perry, Vinay Puduvalli, Gregory N Fuller, Janet M Bruner, Kenneth D Aldape.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22772980      PMCID： PMC4085739          DOI： 10.1007/s00401-012-1011-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  13 in total

1.  Characterization and outcomes of infratentorial malignant glioma: a population-based study using the Surveillance Epidemiology and End-Results database.

Authors:  Justin Rineer; David Schreiber; Kwang Choi; Marvin Rotman
Journal:  Radiother Oncol       Date:  2010-05-05       Impact factor: 6.280

2.  Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.

Authors:  Craig Horbinski; Julia Kofler; Gabrielle Yeaney; Sandra Camelo-Piragua; Sriram Venneti; David N Louis; Arie Perry; Geoffrey Murdoch; Marina Nikiforova
Journal:  Brain Pathol       Date:  2011-03-14       Impact factor: 6.508

3.  Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.

Authors:  David Capper; David Reuss; Jens Schittenhelm; Christian Hartmann; Juliane Bremer; Felix Sahm; Patrick N Harter; Astrid Jeibmann; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2010-11-11       Impact factor: 17.088

4.  Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.

Authors:  David Capper; Felix Sahm; Christian Hartmann; Richard Meyermann; Andreas von Deimling; Jens Schittenhelm
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

5.  Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Authors:  Andrey Korshunov; Jochen Meyer; David Capper; Arne Christians; Marc Remke; Hendrik Witt; Stefan Pfister; Andreas von Deimling; Christian Hartmann
Journal:  Acta Neuropathol       Date:  2009-06-19       Impact factor: 17.088

6.  A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.

Authors:  Sandra Camelo-Piragua; Michael Jansen; Aniruddha Ganguly; James ChulMin Kim; Arjola K Cosper; Dora Dias-Santagata; Catherine L Nutt; A John Iafrate; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2011-02       Impact factor: 3.148

7.  Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies.

Authors:  Craig Horbinski; Lindsey Kelly; Yuri E Nikiforov; Mary Beth Durso; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.341

8.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

Authors:  M Labussière; A Idbaih; X-W Wang; Y Marie; B Boisselier; C Falet; S Paris; J Laffaire; C Carpentier; E Crinière; F Ducray; S El Hallani; K Mokhtari; K Hoang-Xuan; J-Y Delattre; M Sanson
Journal:  Neurology       Date:  2010-04-28       Impact factor: 11.800

Review 9.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Authors:  Nanne K Kloosterhof; Linda B C Bralten; Hendrikus J Dubbink; Pim J French; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2010-07-07       Impact factor: 54.433

10.  Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.

Authors:  Craig Horbinski; Julia Kofler; Lindsey M Kelly; Geoffrey H Murdoch; Marina N Nikiforova
Journal:  J Neuropathol Exp Neurol       Date:  2009-12       Impact factor: 3.148
View more
  25 in total

1.  Adult brainstem gliomas: Correlation of clinical and molecular features.

Authors:  Brett J Theeler; Benjamin Ellezam; Isaac Melguizo-Gavilanes; John F de Groot; Anita Mahajan; Kenneth D Aldape; Janet M Bruner; Vinay K Puduvalli
Journal:  J Neurol Sci       Date:  2015-04-18       Impact factor: 3.181

2.  The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database.

Authors:  Panagiotis Kerezoudis; Anshit Goyal; Victor M Lu; Mohammed Ali Alvi; Mohamad Bydon; Sani H Kizilbash; Terry C Burns
Journal:  J Neurooncol       Date:  2019-12-24       Impact factor: 4.130

Review 3.  Using the molecular classification of glioblastoma to inform personalized treatment.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

4.  Adult pilocytic astrocytomas: clinical features and molecular analysis.

Authors:  Brett J Theeler; Benjamin Ellezam; Zsila S Sadighi; Vidya Mehta; M Diep Tran; Adekunle M Adesina; Janet M Bruner; Vinay K Puduvalli
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

Review 5.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

Review 6.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

7.  IDH1 R132H mutation in a pilocytic astrocytoma: a case report.

Authors:  Felix Behling; Julia Steinhilber; Marcos Tatagiba; Sotirios Bisdas; Jens Schittenhelm
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases.

Authors:  Seth C Lummus; Dara L Aisner; Sharon B Sams; Nicholas K Foreman; Kevin O Lillehei; B K Kleinschmidt-DeMasters
Journal:  Am J Clin Pathol       Date:  2014-08       Impact factor: 2.493

9.  The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.

Authors:  Sani H Kizilbash; Caterina Giannini; Jesse S Voss; Paul A Decker; Robert B Jenkins; John Hardie; Nadia N Laack; Ian F Parney; Joon H Uhm; Jan C Buckner
Journal:  J Neurooncol       Date:  2014-07-04       Impact factor: 4.506

Review 10.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.